193 related articles for article (PubMed ID: 24266694)
1. Afatinib in the treatment of head and neck squamous cell carcinoma.
Ferrarotto R; Gold KA
Expert Opin Investig Drugs; 2014 Jan; 23(1):135-43. PubMed ID: 24266694
[TBL] [Abstract][Full Text] [Related]
2. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
3. A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
Seiwert TY; Fayette J; Cupissol D; Del Campo JM; Clement PM; Hitt R; Degardin M; Zhang W; Blackman A; Ehrnrooth E; Cohen EEW
Ann Oncol; 2014 Sep; 25(9):1813-1820. PubMed ID: 24928832
[TBL] [Abstract][Full Text] [Related]
4. Afatinib in squamous cell carcinoma of the head and neck.
Specenier P; Vermorken J
Expert Opin Pharmacother; 2016 Jun; 17(9):1295-301. PubMed ID: 27160335
[TBL] [Abstract][Full Text] [Related]
5. Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial.
Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Vermorken JB; Clement PM; Gauler T; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Cohen EE;
Lancet Oncol; 2015 May; 16(5):583-94. PubMed ID: 25892145
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck.
Harbeck N; Solca F; Gauler TC
Future Oncol; 2014 Jan; 10(1):21-40. PubMed ID: 24328407
[TBL] [Abstract][Full Text] [Related]
7. Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Michmerhuizen NL; Leonard E; Matovina C; Harris M; Herbst G; Kulkarni A; Zhai J; Jiang H; Carey TE; Brenner JC
Mol Pharmacol; 2019 May; 95(5):528-536. PubMed ID: 30858165
[TBL] [Abstract][Full Text] [Related]
8. Current Role of Dacomitinib in Head and Neck Cancer.
Elicin O; Ozsahin M
Expert Opin Investig Drugs; 2016 Jun; 25(6):735-42. PubMed ID: 27070370
[TBL] [Abstract][Full Text] [Related]
9. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
[TBL] [Abstract][Full Text] [Related]
10. Simultaneously targeting ErbB family kinases and PI3K in HPV-positive head and neck squamous cell carcinoma.
Yang Z; Liao J; Schumaker L; Carter-Cooper B; Lapidus RG; Fan X; Gaykalova DA; Mehra R; Cullen KJ; Dan H
Oral Oncol; 2022 Aug; 131():105939. PubMed ID: 35667295
[TBL] [Abstract][Full Text] [Related]
11. Afatinib versus methotrexate in older patients with second-line recurrent and/or metastatic head and neck squamous cell carcinoma: subgroup analysis of the LUX-Head & Neck 1 trial.
Clement PM; Gauler T; Machiels JP; Haddad RI; Fayette J; Licitra LF; Tahara M; Cohen EE; Cupissol D; Grau JJ; Guigay J; Caponigro F; de Castro G; de Souza Viana L; Keilholz U; Del Campo JM; Cong XJ; Ehrnrooth E; Vermorken JB;
Ann Oncol; 2016 Aug; 27(8):1585-93. PubMed ID: 27084954
[TBL] [Abstract][Full Text] [Related]
12. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
Cohen RB
Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
[TBL] [Abstract][Full Text] [Related]
13. [Afatinib in patients with squamous cell carcinoma of the lung: current context and the option of oral treatment].
Cobo M; Gutiérrez V; Rodelo L; López O; Ruiz M; Godoy A
Med Clin (Barc); 2016 Apr; 146 Suppl 1():25-9. PubMed ID: 27426245
[TBL] [Abstract][Full Text] [Related]
14. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial.
Soria JC; Felip E; Cobo M; Lu S; Syrigos K; Lee KH; Göker E; Georgoulias V; Li W; Isla D; Guclu SZ; Morabito A; Min YJ; Ardizzoni A; Gadgeel SM; Wang B; Chand VK; Goss GD;
Lancet Oncol; 2015 Aug; 16(8):897-907. PubMed ID: 26156651
[TBL] [Abstract][Full Text] [Related]
15. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas.
Martinez-Useros J; Garcia-Foncillas J
Oral Oncol; 2015 May; 51(5):423-30. PubMed ID: 25753560
[TBL] [Abstract][Full Text] [Related]
16. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma.
Chung CH; Rudek MA; Kang H; Marur S; John P; Tsottles N; Bonerigo S; Veasey A; Kiess A; Quon H; Cmelak A; Murphy BA; Gilbert J
Oral Oncol; 2016 Feb; 53():54-9. PubMed ID: 26705063
[TBL] [Abstract][Full Text] [Related]
17. Afatinib radiosensitizes head and neck squamous cell carcinoma cells by targeting cancer stem cells.
Macha MA; Rachagani S; Qazi AK; Jahan R; Gupta S; Patel A; Seshacharyulu P; Lin C; Li S; Wang S; Verma V; Kishida S; Kishida M; Nakamura N; Kibe T; Lydiatt WM; Smith RB; Ganti AK; Jones DT; Batra SK; Jain M
Oncotarget; 2017 Mar; 8(13):20961-20973. PubMed ID: 28423495
[TBL] [Abstract][Full Text] [Related]
18. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
Pernas FG; Allen CT; Winters ME; Yan B; Friedman J; Dabir B; Saigal K; Mundinger GS; Xu X; Morris JC; Calvo KR; Van Waes C; Chen Z
Clin Cancer Res; 2009 Apr; 15(7):2361-72. PubMed ID: 19318490
[TBL] [Abstract][Full Text] [Related]
19. Afatinib as second-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: Subgroup analyses of treatment adherence, safety and mode of afatinib administration in the LUX-Head and Neck 1 trial.
Haddad R; Guigay J; Keilholz U; Clement PM; Fayette J; de Souza Viana L; Rolland F; Cupissol D; Geoffrois L; Kornek G; Licitra L; Melichar B; Ribaldo Nicolau U; Rauch D; Zanetta-Devauges S; Cohen EEW; Machiels JP; Tahara M; Vermorken J; Geng Y; Zografos E; Gauler T
Oral Oncol; 2019 Oct; 97():82-91. PubMed ID: 31450171
[TBL] [Abstract][Full Text] [Related]
20. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]